Add a bookmark to get started

Abstract
18 January 20223 minute read

DLA Piper advises Pack4U in its acquisition of Catalyst Healthcare

DLA Piper represented Pack4U, a connected health services company, in its acquisition of leading pharmacy technology company Catalyst Healthcare.

Pack4U provides in-home and virtual services that connect patients with pharmacists for oversight, medication delivery, remote monitoring and care coordination. The company’s complete suite of connected health IP enables it to help personalize care, improve health outcomes and lower total cost of care across North America. Catalyst Healthcare’s patented AdhereNet® platform links pharmacists, patients and care teams to effectively manage drug complexity and improve medication adherence.

“It was a pleasure to bring together our extensive transactional capabilities and experience in the healthcare sector to advise Pack4U on its acquisition of Catalyst Healthcare, which will enable Pack4U to strengthen its ability to meet the needs of patients, providers and health plans by offering a full, end-to-end, connected care solution,” said Mitchell Marder, the DLA Piper senior counsel who led the firm’s deal team.

In addition to Mitchell Marder (Washington, DC), the DLA Piper team representing Pack4U included Jeffrey Houle (Washington, DC) and Joshua Samek (Miami), as well as partners Alex Roberts and Russel Drew (Toronto), Campbell Fitch (Vancouver), and Witold Jurewicz (New York); and associate Kristen Bandura (Washington, DC).

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex cross-border transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 11 consecutive years, according to Mergermarket.

The firm’s Healthcare sector consists of a multidisciplinary legal team with niche experience in health-related business and legal issues. The team regularly works with corporations and financial institutions, private investors, private equity groups, venture capital funds, institutional investors and portfolio companies in all types of healthcare transactions.

Print